Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 17/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26686474 | 0.88 | ADORA3 (0.50) | L3MBTL1ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL30515308 | 0.87 | ADORA3 (0.49) | L3MBTL1ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL4552644 | 0.80 | LMNA (0.56) | L3MBTL1ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL18658437 | 0.80 | ADORA3 (0.54) | L3MBTL1ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL1766001 | 0.78 | L3MBTL1 (0.52) | L3MBTL1ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL12975420 | 0.76 | L3MBTL1 (0.55) | L3MBTL1 | |
| SCHEMBL4552543 | 0.76 | L3MBTL1 (0.59) | L3MBTL1ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL23274769 | 0.75 | ADORA2A (0.59) | ADORA2AADORA1 | |
| SCHEMBL29762385 | 0.75 | ADORA2A (0.59) | ADORA2AADORA1 | |
| SCHEMBL21728888 | 0.75 | L3MBTL1 (0.48) | L3MBTL1ADORA3ADORA2AADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10442771-B2 | Trans-base tunnel reader for sequencing | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2019-10-15 | — | — | US | disclosed |
| US-20170204066-A1 | NANOPORE BASED SEQUENCER | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2017-07-20 | — | — | US | disclosed |
| US-9593372-B2 | Nanopore based sequencer | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2017-03-14 | — | — | US | disclosed |
| US-20150211059-A1 | TRANS-BASE TUNNEL READER FOR SEQUENCING | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY | 2015-07-30 | — | — | US | disclosed |
| US-8968540-B2 | Trans-base tunnel reader for sequencing | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2015-03-03 | — | — | US | disclosed |
| US-8961757-B2 | Nanopore and carbon nanotube based DNA sequencer | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2015-02-24 | — | — | US | disclosed |
| US-20130186757-A1 | Nanopore and Carbon Nanotube Based Dna Sequencer and A Serial Recognition Elements | ARIZONA BOARD OF REGENTS (US) | 2013-07-25 | — | — | US | disclosed |
| US-20110168562-A1 | Nanopore and Carbon Nanotube Based DNA Sequencer | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY | 2011-07-14 | — | — | US | disclosed |
| US-20110120868-A1 | Nanopore and Carbon Nanotube Based DNA Sequencer and a Serial Recognition Sequencer | ARIZONA BOARD OF REGENTS ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2011-05-26 | — | — | US | disclosed |
| WO-2010042514-A1 | NANOPORE AND CARBON NANOTUBE BASED DNA SEQUENCER AND A SERIAL RECOGNITION ELEMENTS | ARIZONA BOARD OF REGENTS (US) | 2010-04-15 | — | — | WO | disclosed |
| WO-2009117522-A2 | NANOPORE AND CARBON NANOTUBE BASED DNA SEQUENCER AND A SERIAL RECOGNITION SEQUENCER | REINHART, KEVIN (US) | 2009-09-24 | — | — | WO | disclosed |
| WO-2009117517-A2 | NANOPORE AND CARBON NANOTUBE BASED DNA SEQUENCER | ARIZONA BOARD OF REGENTS ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170204066-A1 | NANOPORE BASED SEQUENCER | DNMT3A, DNTT, TELO2 | L3MBTL1 2596/4885ADORA3 3857/4885ADORA2A 4336/4885 |
| US-10442771-B2 | Trans-base tunnel reader for sequencing | DNTT, TRDMT1, TELO2 | L3MBTL1 1043/4885ADORA3 1700/4885ADORA2A 2173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.